10,675 Shares in Phreesia, Inc. (NYSE:PHR) Bought by Ameriprise Financial Inc.

Ameriprise Financial Inc. bought a new position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,675 shares of the company's stock, valued at approximately $269,000.

A number of other institutional investors also recently modified their holdings of the company. Greenhouse Funds LLLP increased its stake in shares of Phreesia by 27.9% during the fourth quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company's stock valued at $72,307,000 after purchasing an additional 626,579 shares in the last quarter. Park West Asset Management LLC bought a new stake in shares of Phreesia during the 4th quarter valued at $10,657,000. ExodusPoint Capital Management LP lifted its stake in shares of Phreesia by 448.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock valued at $4,402,000 after buying an additional 143,077 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in Phreesia by 41.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 484,617 shares of the company's stock worth $12,193,000 after purchasing an additional 141,411 shares in the last quarter. Finally, Barclays PLC lifted its stake in Phreesia by 120.4% in the 4th quarter. Barclays PLC now owns 209,209 shares of the company's stock worth $5,264,000 after purchasing an additional 114,280 shares in the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Stock Performance

PHR opened at $25.80 on Friday. The firm has a market capitalization of $1.54 billion, a PE ratio of -17.55 and a beta of 0.74. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $30.53. The firm's 50-day moving average price is $24.72 and its 200 day moving average price is $25.41. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $115.94 million for the quarter, compared to analyst estimates of $115.00 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia's revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.05) EPS. As a group, sell-side analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PHR. Citigroup restated a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. Canaccord Genuity Group dropped their price objective on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research note on Thursday, May 29th. Needham & Company LLC restated a "buy" rating and issued a $29.00 target price on shares of Phreesia in a research note on Thursday, March 13th. Truist Financial lifted their price objective on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. Finally, Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia currently has a consensus rating of "Buy" and an average price target of $31.64.

Insider Buying and Selling at Phreesia

In other news, General Counsel Allison C. Hoffman sold 1,213 shares of the firm's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total value of $28,881.53. Following the completion of the sale, the general counsel now owns 137,921 shares in the company, valued at approximately $3,283,899.01. This trade represents a 0.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Evan Roberts sold 1,845 shares of the firm's stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $23.81, for a total transaction of $43,929.45. Following the completion of the sale, the chief operating officer now owns 774,807 shares of the company's stock, valued at $18,448,154.67. This trade represents a 0.24% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,474 shares of company stock valued at $1,023,208. Insiders own 5.50% of the company's stock.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.